Elafibranor

Elafibranor
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
Synonyms GFT505, SureCN815512
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C22H24O4S
Molar mass 384.489 g/mol
3D model (JSmol)

Elafibranor (INN,[2] code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).[3][4][5]

Elafibranor is a dual PPARα/δ agonist.[6][7]

Clinical studies

Administered to over 800 patients and healthy volunteers to date, elafibranor has demonstrated:

Phase 2b (GOLDEN) results were published online in Gastroenterology in February 2016[10] and will be fully available in the paper version in May 2016.

As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.[11]

Pre-clinical studies

Efficacy on histological NASH parameters (steatosis, inflammation, fibrosis) in animal disease models — anti-fibrotic activities.[12]

The absence of safety concern has been confirmed in a full toxicological package up to 2-year carcinogenicity studies and cardiac studies (in mice).[13]

See also

References

  1. ↑ Cariou, B.; Zair, Y.; Staels, B.; Bruckert, E. (2011). "Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients with Combined Dyslipidemia or Impaired Glucose Metabolism". Diabetes Care. 34 (9): 2008–2014. PMC 3161281 Freely accessible. PMID 21816979. doi:10.2337/dc11-0093.
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. p. 10. Retrieved 9 November 2016.
  3. ↑ "Advanced Compound Status" (Press release). Genfit.
  4. ↑ "GFT505 Broadens Its Therapeutic Potential" (PDF) (Press release). Retrieved 31 Mar 2013.
  5. ↑ Cariou, Bertrand; Staels, Bart (2014-10-01). "GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes". Expert Opinion on Investigational Drugs. 23 (10): 1441–1448. ISSN 1744-7658. PMID 25164277. doi:10.1517/13543784.2014.954034.
  6. ↑ US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641" (PDF). Retrieved 31 Mar 2013.
  7. ↑ "GFT-505" (PDF). Drugs of the Future. 37 (8): 555–559. 2012.
  8. ↑ Staels, Bart; Rubenstrunk, Anne; Noel, Benoit; Rigou, Géraldine; Delataille, Philippe; Millatt, Lesley J.; Baron, Morgane; Lucas, Anthony; Tailleux, Anne (2013-12-01). "Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis". Hepatology. 58 (6): 1941–1952. ISSN 1527-3350. doi:10.1002/hep.26461.
  9. ↑ Cariou, Bertrand; Hanf, Rémy; Lambert-Porcheron, Stéphanie; Zaïr, Yassine; Sauvinet, Valérie; Noël, Benoit; Flet, Laurent; Vidal, Hubert; Staels, Bart (2013-05-28). "Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects". Diabetes Care. 36: DC_122012. ISSN 0149-5992. PMC 3781493 Freely accessible. PMID 23715754. doi:10.2337/dc12-2012.
  10. ↑ "Elafibranor, an Agonist of the Peroxisome Proliferator-activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening - Gastroenterology". www.gastrojournal.org. Retrieved 2016-03-08.
  11. ↑ clinical trials involving GFT505
  12. ↑ Quintero, Pablo; Arrese, Marco (2013-12-01). "Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism". Hepatology (Baltimore, Md.). 58 (6): 1881–1884. ISSN 1527-3350. PMID 23787705. doi:10.1002/hep.26582.
  13. ↑ Hanf, Rémy; Millatt, Lesley J.; Cariou, Bertrand; Noel, Benoit; Rigou, Géraldine; Delataille, Philippe; Daix, Valérie; Hum, Dean W.; Staels, Bart (2014-11-01). "The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects". Diabetes & Vascular Disease Research. 11 (6): 440–447. ISSN 1752-8984. PMID 25212694. doi:10.1177/1479164114548027.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.